Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALADIN-DAPTCLTI trial of dual antiplatelet therapy duration after distal revascularization in chronic limb-threatening ischemia
2025-524297-42-00Phase 3Authorised
- Sponsor
- Fondation Hôpital Saint-Joseph
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clopidogrel in arteriosclerosis obliterans and chronic limb-threatening ischemia (CLTI) (2 arms), sponsored by Fondation Hôpital Saint-Joseph. Primary endpoint: Amputation-free survival at 12 months. Planned start Mar 2026; status: authorised.
02
Drugs
clopidogrel
03
Conditions
arteriosclerosis obliteranschronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2025-524297-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524297-42-00.